Category: 3. Business

  • Offshore wind buffeted by economic and political storms

    Offshore wind buffeted by economic and political storms

    The North Sea boasts some of the world’s best wind speeds for power generation, averaging more than 9 metres a second. But when the German government offered two prime spots to offshore developers this summer, it did not receive a single bid.

    The auction’s failure in August marked a stark contrast to two years earlier, when oil companies BP and TotalEnergies agreed to pay a total €12.6bn for the rights to develop two large wind farms in German waters in the North Sea and Baltic Sea. 

    The industry’s enthusiasm has collapsed as higher interest rates and supply chain strains stretch the business case for projects to breaking point and political support sours in the US, where President Donald Trump has sought to block developments and suspend permits. 

    “Offshore wind has been going through a challenging time,” said Sven Utermöhlen, head of offshore wind at German energy company RWE, which has frozen its US offshore wind investment plans as it seeks to move away from coal.

    “This has been predominately driven by rising costs, but also an overarching political climate where the fight against climate change and the drive for decarbonisation and energy transition has somewhat slowed down and has made space for other priorities.”

    Since 2023, 24.1 gigawatts of offshore wind capacity and offtake agreements have been cancelled, according to figures from energy consultancy Wood Mackenzie. One gigawatt can power the equivalent of 1mn UK homes.

    Ambitious government targets for the technology appear out of reach, raising questions over the pace of efforts to shift away from fossil fuels and reduce the world’s carbon dioxide emissions.

    Wood Mackenzie estimates that outside of China, roughly 100GW of installed capacity could be up and running by 2030 — 140GW short of global targets for total installed capacity that year.

    Some content could not load. Check your internet connection or browser settings.

    The industry’s struggles come after rapid growth in the rock-bottom interest rate environment of the 2010s and early 2020s, with installed capacity growing from about 3GW in 2010 to 78.5GW by the end of last year, about half of which is in China. Meanwhile, developers competing for new seabed projects and government contracts squeezed supply chains to push down costs.

    Those dynamics have shifted since the coronavirus pandemic, as interest rates surged and companies in an overstretched supply chain pushed back. Analysts at TGS 4C say the industry’s capital expenditure has climbed to €3mn per megawatt, up from €2.5mn in 2022.

    Projects have been cancelled or their valuations have dropped, while developers have shunned government offshore wind auctions from the Netherlands and Denmark to India. At the same time, oil companies have doubled down on fossil fuels.

    Denmark’s Ørsted, the world’s largest offshore wind developer, has had to raise an extra $9bn from investors and this month said it would cut a quarter of its 8,000-strong workforce. London-headquartered Corio Generation, backed by Macquarie, has cut jobs, while Spanish developer BlueFloat Energy has quit the market.

    The industry’s troubles contrast with the breakneck growth of solar power, which the International Energy Agency expects to account for 80 per cent of the projected addition of 4,600GW in global renewables capacity this decade, fuelled by falling costs and relatively straightforward permitting.

    The offshore wind industry’s future hinges on the extent to which governments, utilities and corporate customers support the higher costs, helping to provide the industry and supply chain with the certainty it needs to invest.

    “The central sticking point is how to distribute costs and risks between developers and taxpayers,” analysts at TGS 4C said in a recent report.

    A worker in safety gear walks beside a large wind turbine monopile foundation being transported at the EEW Special PipeConstructions premises.
    Wind turbine foundations being transported in Germany © Frank Soellner/Getty Images

    Denmark and Germany have both decided to offer support in the form of government-backed contracts-for-difference, to try to avoid repeats of failed auctions.

    Under the contracts, pioneered in the UK, developers are guaranteed a fixed price for electricity but have to pay back the difference if the wholesale price they can sell electricity for is higher.

    Many developers see such contracts as the best way to develop offshore wind given the stability they provide. Søren Lassen, head of wind at Wood Mackenzie said: “You’re really looking at the CFD as the option if you want to deliver renewables at the scale that the governments are still projecting.”

    Vietnam is also introducing the contracts as it tries to get its offshore wind industry off the ground. It is part of a push in Asia, including in the Philippines and South Korea, which along with some tempering of interest rates and other costs has boosted optimism in the sector.

    “I am encouraged,” said Ben Backwell, chief executive of the Global Wind Energy Council trade group. “We have got over a lot of the humps we were facing.”

    Rasmus Errboe, the chief executive of Ørsted, who has warned of the risk of a “downward spiral” in the industry, this month said he remained “bullish” about its future.

    The IEA also this month downgraded its growth outlook for offshore wind from 212GW to 140GW by 2030. But the reduced pace would still be more than double that of the previous five years.

    Industry advisers and executives are hopeful the shakeout of projects and failed auctions has put the industry on a more sustainable footing, by weeding out bad market mechanisms and undisciplined players.

    Line chart of Cancelled offshore wind offtake capacity (MW)  showing Several major offshore wind projects have been pulled

    “Bad auction designs are disappearing because there’s no optimism that would make people tolerate them,” said Jérôme Guillet, director at boutique advisory firm Snow. “People that actually want to do offshore wind will do offshore wind now and it makes sense in some countries with the new stabilised current project economics.”

    Political support, however, is increasingly fragile.

    In Britain, the world’s second-largest offshore wind market, the decision to raise the maximum prices in an upcoming CfD auction to fend off a repeat of a failed auction in 2023 has prompted criticism from the government’s opponents. Insurgent rightwing party Reform, which is leading in the polls, has warned that it could “strike down” the contracts. The speed of obtaining permits and grid connections also remains a challenge.

    Meanwhile, the prospects for the industry in the US have taken a nosedive under Trump, who has described wind as the “worst form” of energy and frozen seabed leasing for offshore developments.

    His government in April ordered Norway’s Equinor to stop work on its Empire Wind project off the coast of New York, before allowing it to go ahead in May. In August, it ordered Ørsted to stop work on its Revolution Wind project, although a judge has persuaded the court to lift the order for now.

    Leading turbine manufacturers such as Spain-based Siemens Gamesa and Denmark’s Vestas are investing in new capacity. But TGS warns that there is still likely to be a shortfall unless Chinese manufacturers expand further into global markets.

    Trade disputes and geopolitical concerns could get in the way of that. Europe is investigating whether China’s wind turbine makers are receiving unfair subsidies, while Chris Wright, the US energy secretary, has urged countries to buy less technology from China, telling reporters recently that “the goal of the US and our allies is to reduce our dependence on imports from China”.

    Nonetheless, RWE’s Utermöhlen argues that factors in the sector’s favour, such as its ability to supply homegrown power during more hours of the day than solar, and from father away from people’s homes, will continue to propel the industry.

    “The fundamentals are intact,” he said, but the industry needed “to get to a sustainable growth path” where supply and demand were balanced. “That will mean the growth trajectory is less steep than it was envisaged but that would be sustainable.”

    Climate Capital

    Where climate change meets business, markets and politics. Explore the FT’s coverage here.

    Are you curious about the FT’s environmental sustainability commitments? Find out more about our science-based targets here

    Continue Reading

  • Chinese tech giants pause stablecoin plans after Beijing steps in, FT reports

    Chinese tech giants pause stablecoin plans after Beijing steps in, FT reports

    Oct 18 (Reuters) – Chinese tech giants, including Alibaba-backed Ant Group (688688.SS), opens new tab and e-commerce group JD.com (9618.HK), opens new tab, have paused plans to issue stablecoins in Hong Kong after the government raised concerns about the rise of currencies controlled by the private sector, the Financial Times reported on Saturday.

    Companies have put their stablecoin ambitions on hold after receiving instructions from Chinese regulators, including the People’s Bank of China and Cyberspace Administration of China, not to move ahead with the plans, the FT reported, citing people familiar with the matter.

    Sign up here.

    Hong Kong’s legislature passed a stablecoin bill in May that established a licensing regime for fiat-referenced stablecoin issuers in Hong Kong, providing regulatory clarity for future participants.

    Under the new regime, any person who issues stablecoins in Hong Kong – or issues stablecoins backed by Hong Kong dollars, whether within or outside the city – must obtain a licence from the Hong Kong Monetary Authority.

    Ant Group said in June it would be participating in the pilot stablecoin programme. JD.com has also said it would take part in the pilot, according to the FT.

    PBOC officials advised against participating in the initial rollout of stablecoins over concerns about allowing tech groups and brokerages to issue any type of currency, the FT report said.

    Reuters could not immediately verify the report. Ant Group, JD.com, PBOC, CAC and HKMA did not respond to requests for comment.

    Stablecoins, a type of cryptocurrency designed to maintain a constant value, usually pegged to a fiat currency such as the U.S. dollar, are commonly used by crypto traders to move funds between tokens.

    Reporting by Chandni Shah in Bengaluru, Editing by Franklin Paul, Michael Perry and Christian Schmollinger

    Our Standards: The Thomson Reuters Trust Principles., opens new tab

    Continue Reading

  • Nexperia says Chinese unit operating as usual as tensions with the Netherlands run high – Reuters

    1. Nexperia says Chinese unit operating as usual as tensions with the Netherlands run high  Reuters
    2. In rare move, Dutch government takes control of China-owned chipmaker Nexperia  Reuters
    3. New Threat to Auto Sector; AI’s DIY Power; IKEA Prices  富途牛牛
    4. Dutch government in talks with China over crucial automotive chip supplier Nexperia  Automotive News
    5. Nexperia crisis: Semiconductor supply shock threatens global auto production  Automotive Manufacturing Solutions

    Continue Reading

  • EROAD (NZSE:ERD) Is Down 31.9% After Guidance Cut and North American Impairments – What’s Changed

    EROAD (NZSE:ERD) Is Down 31.9% After Guidance Cut and North American Impairments – What’s Changed

    • In a recent announcement, EROAD downgraded its fiscal 2026 revenue guidance, reported up to NZ$150 million in North American asset impairments, and outlined a renewed focus on Australia and New Zealand alongside scaled-back North American activities.

    • This shift comes as challenges in North America, including a key customer loss and slower enterprise sales, prompt the company to reallocate resources toward emerging opportunities in its core markets.

    • With the company’s refocus on electronic road user charging in Australia and New Zealand, we’ll examine how this shapes EROAD’s investment narrative.

    Trump’s oil boom is here – pipelines are primed to profit. Discover the 22 US stocks riding the wave.

    To be comfortable holding EROAD shares right now, you’d need conviction in its ability to execute a fresh regional pivot following major shortfalls in North America. The company’s reset, moving growth focus and resources to Australia and New Zealand’s road user charging opportunities, marks a fundamental shift in its investment story. While previous catalysts centered on U.S. expansion and telematics innovation, the market’s sharp reaction to asset impairments and guidance cuts suggests near-term growth drivers will depend on how quickly EROAD can win or retain clients and secure contracts linked to new charging regimes in its home markets. The immediate risk is execution: reestablishing momentum in Australia and New Zealand is not guaranteed, and the heavy NZ$150 million impairment underscores uncertainty over any future North American contributions. The recent share price drop signals these risks are now firmly front and center for investors. On the flip side, the road to recovery in core markets comes with its own hurdles investors need to keep front of mind.

    Despite retreating, EROAD’s shares might still be trading 43% above their fair value. Discover the potential downside here.

    NZSE:ERD Community Fair Values as at Oct 2025

    Seven members of the Simply Wall St Community estimate EROAD’s fair value anywhere from NZ$1.20 to NZ$4.96 per share. This wide range reflects big differences in expectations around EROAD’s growth rebound in Australia and New Zealand after its US setback. Comparing such varied outlooks with the company’s new strategic focus, it pays to see how your own view lines up.

    Explore 7 other fair value estimates on EROAD – why the stock might be worth over 2x more than the current price!

    Disagree with this assessment? Create your own narrative in under 3 minutes – extraordinary investment returns rarely come from following the herd.

    • A great starting point for your EROAD research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

    • Our free EROAD research report provides a comprehensive fundamental analysis summarized in a single visual – the Snowflake – making it easy to evaluate EROAD’s overall financial health at a glance.

    These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include ERD.nzse.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • Pembrolizumab Plus Lenvatinib Shows Encouraging Efficacy in Uveal Melanoma | Targeted Oncology

    Pembrolizumab Plus Lenvatinib Shows Encouraging Efficacy in Uveal Melanoma | Targeted Oncology

    The combination of pembrolizumab (Keytruda) and lenvatinib (Lenvima) elicited promising progression-free survival (PFS) outcomes in patients with uveal melanoma who were both HLA-A*02:01–negative and –positive with a manageable safety profile, according to findings from the phase 2 PLUME trial (NCT05282901) presented at the 2025 ESMO Congress.1

    The study met its primary end point in both patient cohorts, with an observed PFS rate of 31.8% at 27 weeks (95% CI, 13.9%-54.9%) in patients who were HLA-A*02:01–negative and naïve for treatment with tebentafusp (Kimtrak). In patients who were HLA-A*02:01–positive and were pretreated with tebentafusp, the PFS rate at 27 weeks was 60.7% (95% CI, 40.6%-78.5%).

    “It was observed in phase 3 studies of tebentafusp2 that treatments administered after tebentafusp might display improved activity compared [with] historical data,” said Manuel Rodrigues, MD, medical oncologist at Institut Curie and presenter of the PLUME data.1

    The combination of lenvatinib and pembrolizumab “showed encouraging activity, especially in patients previously treated with tebentafusp, suggesting potential synergy between these treatments,” Rodrigues added.

    Regarding safety, the overall profile was consistent with prior trials involving pembrolizumab and lenvatinib. There were no treatment-related deaths. With lenvatinib, 76% of patients held the dose, 26% had dose reductions, and 4% discontinued. With pembrolizumab, 22% of patients held the dose and 4% discontinued.

    The most common any-grade treatment-related adverse events were fatigue (81.8% in the tebentafusp-naive cohort vs 69% in the pretreated cohort), hypertension (77.3% vs 69%), diarrhea (45.5% vs 65.5%), hypothyroidism (45.5% vs 65.5%), arthralgia (40.9% vs 58.6%), cytolytic hepatitis (40.9% vs 58.6%), mucositis (45.5% vs 41.4%), dysphonia (31.8% vs 44.8%), and abdominal pain (27.3% vs 44.8%).

    While the findings were promising, Rodrigues urged caution when interpreting the results, due to the small sample size and single-arm design. Rodrigues noted that biomarker analyses and real-world comparisons were ongoing to further refine patient selection.

    What Was the Design of the PLUME Study?

    PLUME was an academic, monocentric, single-arm phase 2 trial conducted at the Institut Curie in Paris, France.A total of 51 patients who were naïve to immune checkpoint inhibitors were enrolled and split into 2 cohorts by HLA-A*02:01–negative (n = 22) and –positive/pretreated with tebentafusp (n = 29).

    Treatment consisted of pembrolizumab 200 mg intravenously every 3 weeks for a maximum of 35 cycles and lenvatinib 20 mg orally daily until progression. Chest, abdomen, and pelvic CT scans and liver MRIs were mandatory every 9 weeks. The primary end point was 27-week PFS (after 9 cycles).

    What Was the Rationale for the PLUME Study?

    As Rodrigues explained in his presentation, uveal melanoma has a unique biology to melanoma of the skin, with one-third of patients developing metastases and over 90% of those patients developing liver metastases. The current median overall survival (OS)is about 20 months.

    Tebentafusp, a bispecific TCR–anti-CD3 fusion protein targeting gp100, was the first therapy to improve OS in patients with metastatic uveal melanoma; however, the benefit is limited to patients who are HLA-A*02:01–positive, which is about 45% of patients. Further, checkpoint inhibitors like pembrolizumab have shown limited efficacy due to low mutational burden and an immunosuppressive microenvironment.

    The rationale of adding lenvatinib lies in its VEGFR/FGRF blockade that can normalize vasculature, reduce tumor-associated macrophages, and enhance T-cell infiltration. The combination of lenvatinib and pembrolizumab has shown promise in endometrial and renal cancers, where the combination has outperformed monotherapy.

    DISCLOSURES: Rodrigues declared personal financial interests with Immunocore, GSK, AstraZeneca, and Abbvie; institutional financial interests with Johnson & Johnson, Merck, and Daiichi-Sankyo; and nonfinancial interests with Merck, which provided product samples for the PLUME trial.

    REFERENCES:

    1. Rodrigues M. PLUME: A single-arm phase II trial of pembrolizumab plus lenvatinib in metastatic uveal melanoma (mUM). Presented at: 2025 ESMO Congress; October 17–20, 2025; Berlin, German. Abstract LBA58.

    2. Nathan P, Hassel JC, Rutkowski P, et al. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med. 2021 Sep 23;385(13):1196-1206. doi: 10.1056/NEJMoa2103485.

    Continue Reading

  • Insiders own 30% of Master Tec Group Berhad (KLSE:MTEC) shares but private companies control 55% of the company

    Insiders own 30% of Master Tec Group Berhad (KLSE:MTEC) shares but private companies control 55% of the company

    • The considerable ownership by private companies in Master Tec Group Berhad indicates that they collectively have a greater say in management and business strategy

    • MTPC Sdn Bhd owns 55% of the company

    • Insiders own 30% of Master Tec Group Berhad

    Trump has pledged to “unleash” American oil and gas and these 15 US stocks have developments that are poised to benefit.

    Every investor in Master Tec Group Berhad (KLSE:MTEC) should be aware of the most powerful shareholder groups. And the group that holds the biggest piece of the pie are private companies with 55% ownership. Put another way, the group faces the maximum upside potential (or downside risk).

    Individual insiders, on the other hand, account for 30% of the company’s stockholders. Institutions often own shares in more established companies, while it’s not unusual to see insiders own a fair bit of smaller companies.

    Let’s delve deeper into each type of owner of Master Tec Group Berhad, beginning with the chart below.

    See our latest analysis for Master Tec Group Berhad

    KLSE:MTEC Ownership Breakdown October 19th 2025

    Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

    Less than 5% of Master Tec Group Berhad is held by institutional investors. This suggests that some funds have the company in their sights, but many have not yet bought shares in it. If the company is growing earnings, that may indicate that it is just beginning to catch the attention of these deep-pocketed investors. We sometimes see a rising share price when a few big institutions want to buy a certain stock at the same time. The history of earnings and revenue, which you can see below, could be helpful in considering if more institutional investors will want the stock. Of course, there are plenty of other factors to consider, too.

    earnings-and-revenue-growth
    KLSE:MTEC Earnings and Revenue Growth October 19th 2025

    We note that hedge funds don’t have a meaningful investment in Master Tec Group Berhad. Looking at our data, we can see that the largest shareholder is MTPC Sdn Bhd with 55% of shares outstanding. With such a huge stake in the ownership, we infer that they have significant control of the future of the company. In comparison, the second and third largest shareholders hold about 19% and 3.6% of the stock. Kim San Lau, who is the second-largest shareholder, also happens to hold the title of Senior Key Executive.

    While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock’s expected performance. As far as we can tell there isn’t analyst coverage of the company, so it is probably flying under the radar.

    Continue Reading

  • Assessing Celestica (TSX:CLS) Valuation After Strong Share Price Surge

    Assessing Celestica (TSX:CLS) Valuation After Strong Share Price Surge

    Celestica (TSX:CLS) shares have moved recently, catching the attention of investors interested in tech services and manufacturing. The company’s strong performance this year prompts a closer look at what is driving returns.

    See our latest analysis for Celestica.

    Celestica’s impressive surge has fueled fresh optimism among tech investors. While the 1-year share price return stands at a remarkable 189.8%, the 1-year total shareholder return is even higher at 387.5%. Momentum is clearly building, thanks to robust growth and an improving outlook.

    If you’re looking to uncover more opportunities in the technology and AI space, the Simply Wall St Tech & AI Growth screener is an excellent next step: See the full list for free.

    With shares posting such rapid gains, the key question is whether Celestica remains undervalued today or if the market has already priced in all of its future growth. This leaves investors pondering if there is still a buying opportunity.

    Celestica’s widely followed narrative suggests a fair value that sits just above the last close price, hinting the stock may still hold some upside even after rapid gains. With the company’s outlook now shaped by bullish projections and improved profitability, attention is turning to major catalysts that could drive further revaluation.

    Accelerated demand for advanced networking and AI infrastructure by hyperscaler customers is driving rapid growth in Celestica’s CCS segment, with multiple new 800G and upcoming 1.6T program ramps. This is supporting robust revenue expansion and greater operating leverage over the next 12 to 24 months.

    Read the complete narrative.

    Want to know which financial levers are fueling this premium? The key story centers on aggressive profit projections and a rare profit multiple normally reserved for industry leaders. Are these bold future assumptions enough to support such an optimistic valuation? Uncover the figures and see what drives this surprising fair value call.

    Result: Fair Value of $402.69 (UNDERVALUED)

    Have a read of the narrative in full and understand what’s behind the forecasts.

    However, market concentration among top customers and heavy reliance on sustained AI investment could quickly challenge Celestica’s bullish growth assumptions.

    Find out about the key risks to this Celestica narrative.

    While the fair value estimate hints at Celestica being undervalued, comparing its price-to-earnings ratio presents a different perspective. The company is trading at 59.3x earnings, almost double the industry average of 30.7x and well above the fair ratio of 53.3x. When a stock trades significantly above its peers and what is considered fair, there is a real risk the price could revert or stall if growth expectations slip. Is this future premium fully justified?

    See what the numbers say about this price — find out in our valuation breakdown.

    TSX:CLS PE Ratio as at Oct 2025

    If you think there’s another angle to the Celestica story or want to dig into the details yourself, you can shape your own view in just a few minutes by using the following resource: Do it your way

    A good starting point is our analysis highlighting 2 key rewards investors are optimistic about regarding Celestica.

    Smart investors never settle for just one opportunity. Make the most of your next move and uncover high-potential stocks using these powerful tools today.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include CLS.TO.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • Examining Valuation After Recent 6% Stock Climb

    Examining Valuation After Recent 6% Stock Climb

    Open Text (NasdaqGS:OTEX) stock has caught some attention in recent weeks, thanks in part to a steady uptick of 6% over the past month. Investors seem interested in the company’s consistent revenue and growing net income.

    See our latest analysis for Open Text.

    Momentum is clearly building for Open Text, with the stock posting a 6.35% share price return over the past month and an impressive 37.14% gain in the last 90 days. When you step back, the one-year total shareholder return of 18.94% and a standout 53.44% total return over three years show that investors who have stuck with the company have seen strong long-term rewards.

    If steady progress like this has you scanning the horizon, now is the perfect moment to broaden your search and discover fast growing stocks with high insider ownership

    The question now is whether Open Text’s recent run suggests there is more value left on the table, or if markets have already priced in the company’s future growth potential. Is there a new buying opportunity emerging?

    With the recent close at $39.03 and a consensus fair value of $37.66, the most widely tracked narrative suggests Open Text’s market price now closely matches analysts’ calculated fundamentals. This balance indicates the market may have already caught up to the company’s projected growth story.

    “Expanded integration of AI and automation capabilities (e.g., Titanium X and MyAviator platforms) directly into OpenText’s cloud suite is leading to higher per-customer spend and driving pipeline conversion rates. These developments are expected to fuel both top-line revenue acceleration and incremental margin improvement.”

    Read the complete narrative.

    Craving the full blueprint behind this pricing? Behind the scenes, ambitious growth targets, aggressive AI and cloud overhaul, and bold margin forecasts set the tone. Want to know which key financial levers support this price and where the tensions truly lie? Dive in to see the numbers driving the narrative’s fair value verdict.

    Result: Fair Value of $37.66 (ABOUT RIGHT)

    Have a read of the narrative in full and understand what’s behind the forecasts.

    However, execution risks from leadership transitions and challenges in revitalizing slower-growth business areas could temper Open Text’s momentum if these issues are not carefully managed.

    Find out about the key risks to this Open Text narrative.

    While multiples suggest Open Text is fairly valued, our SWS DCF model paints a different picture. According to this approach, the stock trades at a hefty 41% discount to its estimated fair value, which is an intriguing disconnect that could signal a hidden opportunity. Could the market be missing something?

    Look into how the SWS DCF model arrives at its fair value.

    OTEX Discounted Cash Flow as at Oct 2025

    If you have a different perspective, or want to dive deeper into the data and craft your own story, it only takes a few minutes to build your own view. Do it your way.

    A great starting point for your Open Text research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.

    Give yourself the edge by tapping into new markets and trends. Don’t let tomorrow’s big winners pass you by when smarter opportunities are within reach.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include OTEX.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • Examining Valuation After Recent 6% Stock Climb

    Examining Valuation After Recent 6% Stock Climb

    Open Text (NasdaqGS:OTEX) stock has caught some attention in recent weeks, thanks in part to a steady uptick of 6% over the past month. Investors seem interested in the company’s consistent revenue and growing net income.

    See our latest analysis for Open Text.

    Momentum is clearly building for Open Text, with the stock posting a 6.35% share price return over the past month and an impressive 37.14% gain in the last 90 days. When you step back, the one-year total shareholder return of 18.94% and a standout 53.44% total return over three years show that investors who have stuck with the company have seen strong long-term rewards.

    If steady progress like this has you scanning the horizon, now is the perfect moment to broaden your search and discover fast growing stocks with high insider ownership

    The question now is whether Open Text’s recent run suggests there is more value left on the table, or if markets have already priced in the company’s future growth potential. Is there a new buying opportunity emerging?

    With the recent close at $39.03 and a consensus fair value of $37.66, the most widely tracked narrative suggests Open Text’s market price now closely matches analysts’ calculated fundamentals. This balance indicates the market may have already caught up to the company’s projected growth story.

    “Expanded integration of AI and automation capabilities (e.g., Titanium X and MyAviator platforms) directly into OpenText’s cloud suite is leading to higher per-customer spend and driving pipeline conversion rates. These developments are expected to fuel both top-line revenue acceleration and incremental margin improvement.”

    Read the complete narrative.

    Craving the full blueprint behind this pricing? Behind the scenes, ambitious growth targets, aggressive AI and cloud overhaul, and bold margin forecasts set the tone. Want to know which key financial levers support this price and where the tensions truly lie? Dive in to see the numbers driving the narrative’s fair value verdict.

    Result: Fair Value of $37.66 (ABOUT RIGHT)

    Have a read of the narrative in full and understand what’s behind the forecasts.

    However, execution risks from leadership transitions and challenges in revitalizing slower-growth business areas could temper Open Text’s momentum if these issues are not carefully managed.

    Find out about the key risks to this Open Text narrative.

    While multiples suggest Open Text is fairly valued, our SWS DCF model paints a different picture. According to this approach, the stock trades at a hefty 41% discount to its estimated fair value, which is an intriguing disconnect that could signal a hidden opportunity. Could the market be missing something?

    Look into how the SWS DCF model arrives at its fair value.

    OTEX Discounted Cash Flow as at Oct 2025

    If you have a different perspective, or want to dive deeper into the data and craft your own story, it only takes a few minutes to build your own view. Do it your way.

    A great starting point for your Open Text research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.

    Give yourself the edge by tapping into new markets and trends. Don’t let tomorrow’s big winners pass you by when smarter opportunities are within reach.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include OTEX.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • Belzutifan demonstrates strong clinical activity in two rare neuroendocrine tumors

    Belzutifan demonstrates strong clinical activity in two rare neuroendocrine tumors

    A multicenter Phase II clinical trial led by researchers at The University of Texas MD Anderson Cancer Center demonstrated significant tumor shrinkage and disease control in patients with advanced pheochromocytoma and paraganglioma (PPGL), two rare and potentially life-threatening neuroendocrine tumors.

    The results of this study, led by Camilo Jimenez, M.D., professor of Endocrine Neoplasia and Hormonal Disorders, were published today in the New England Journal of Medicine and presented concurrently at the 2025 European Society for Medical Oncology (ESMO) Congress (Abstract 1705O).

    What was the primary finding of the trial?

    The trial demonstrated that the HIF-2α inhibitor belzutifan showed meaningful antitumor activity with a 26% objective response rate, a significant achievement particularly for rare and difficult-to-treat cancers. These effects lasted an average of more than 20 months, indicating a sustained clinical benefit for those who responded to treatment.

    It’s notable that nearly one-third of patients (32%) who were taking blood pressure medication were able to reduce their dosage by half for at least six months. This is an important finding, as PPGL tumors often produce excess hormones that raise blood pressure. These results suggest that belzutifan may have also helped manage symptoms related to hormone-secreting tumors.

    The primary significance of this study is demonstrating that HIF-2α inhibition with belzutifan can achieve meaningful clinical benefit in patients with advanced, progressive PPGL. In a population with no remaining standard-of-care options, we observed durable disease control and a manageable safety profile, supporting the rationale for HIF-2α as a therapeutic target in this rare tumor type.”


    Camilo Jimenez, M.D., Professor of Endocrine Neoplasia and Hormonal Disorders

    Why is the LITESPARK-015 trial important?

    Pheochromocytoma and paraganglioma (PPGL) are difficult-to-treat cancers that affect roughly 2,000 people annually in the U.S. One of the main drivers of tumor growth in PPGL is the HIF-2α protein. In healthy cells this protein adjusts to changes in oxygen levels, but genetic mutations or changes in cell metabolism can cause HIF-2α to become abnormally active, triggering signals that help the tumor grow and spread.

    HIF-2α inhibitors, such as belzutifan, have been successful in shrinking tumors and slowing disease progression in other cancers driven by HIF-2α overactivity, such as kidney cancer and von Hippel-Lindau (VHL) disease. Building on this knowledge, researchers evaluated the effectiveness of these inhibitors in patients with advanced PPGL.

    On the LITESPARK-015 Phase II trial, 72 patients with locally advanced, metastatic, unresectable PPGL who had exhausted all other standard-of-care treatment, were treated with belzutifan.

    Is belzutifan approved to treat PPGL?

    In May 2025, the Food and Drug Administration (FDA) approved belzutifan for the treatment of adult and pediatric patients ages 12 years and older with advanced, unresectable, or metastatic PPGL who do not require immediate surgery. Belzutifan is the first oral and only approved therapy for this disease, making it a new standard of care for this patient population. 

    “The approval of belzutifan offers new hope. As an oral treatment, it has been shown to shrink tumors, reduce symptoms, and improve quality of life with low toxicity. It represents a meaningful step forward in care for people living with these rare cancers,” Jimenez said.

    Timeline

    2025 – FDA approves belzutifan for treatment of adult and pediatric patients 12 years and older with PPGL

    2023 – FDA approves belzutifan for advanced renal cell carcinoma (RCC) after treatment with a PD‑1/PD‑L1 inhibitor and a VEGF tyrosine kinase inhibitor (VEGF‑TKI)

    2021 – FDA approves belzutifan for adults with von Hippel‑Lindau (VHL) disease who require treatment for associated tumors (RCC, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors), when surgery is not immediately necessary

    Source:

    University of Texas M. D. Anderson Cancer Center

    Journal reference:

    Jimenez, C., et al. (2025). Belzutifan for Advanced Pheochromocytoma or Paraganglioma. New England Journal of Medicine. doi.org/10.1056/nejmoa2504964

    Continue Reading